ALPHA-L-FUCOSIDE FUCOHYDROLASE

Base Information

• Chemical Name: ALPHA-L-FUCOSIDE FUCOHYDROLASE
• CAS No.: 9037-65-4
• Molecular Weight: 0
• Mol file: 9037-65-4.mol

Synonyms:E.C.3.2.1.51; a-Fucosidase; a-L-Fucosidase

Chemical Property of ALPHA-L-FUCOSIDE FUCOHYDROLASE

Chemical Property:

• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: 2-8°C

Purity/Quality:

98%,99%, ^*data from raw suppliers

α-1,6-Fucosidase solution from Elizabethkingia miricola recombinant, expressed in E. coli, buffered aqueous solution ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• General Description: ALPHA-L-FUCOSIDE FUCOHYDROLASE (also known as α-L-fucosidase or E.C.3.2.1.51) is an enzyme involved in the hydrolysis of α-L-fucosidic linkages in fucose-containing glycoconjugates, playing a role in various physiological and pathological processes. It is a target for selective inhibitors, such as 3-substituted L-fuco-azafagomines, which demonstrate competitive inhibition potential, as evidenced by studies on bovine kidney α-L-fucosidase. These findings suggest its relevance in therapeutic applications targeting fucose-related metabolic pathways.

Refernces

Synthesis of novel 3-amino(hydroxy)methyl- l - Fuco -azafagomines as leads for selective inhibitors of α- L -fucosidases

10.1055/s-0029-1219906

The study reports the synthesis of 3-substituted L-fuco-azafagomines from D-lyxose, representing the first example of aza-C-glycosides with a biimino moiety. These compounds are potential selective inhibitors of a-L-fucosidases, enzymes involved in the biosynthetic processing of fucose-containing glycoconjugates and associated with various physiological and pathological events. The key step in the synthesis involves reductive hydrazination of a 1-deoxy-ketohexose with tert-butyl carbazate. The synthesized compounds, 3a and 3b, were tested for their inhibitory activities against twelve glycosidases, with 3a showing selective and competitive inhibition of a-L-fucosidase from bovine kidney. The study highlights the potential of these compounds as leads for developing new therapeutic agents targeting a-L-fucosidases.